MRI-based sector analysis enhances prostate palladium-103 brachytherapy quality assurance in a phase II prospective trial of men with intermediate-risk localized prostate cancer

Brachytherapy

Volumn 13, Issue 1, 2014, Pages 68-74

  Takiar, Vinita ^a   Pugh, Thomas J ^a   Swanson, David ^a   Kudchadker, Rajat J ^a   Bruno, Teresa L ^a   McAvoy, Sarah ^a   Mahmood, Usama ^a   Frank, Steven J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Brachytherapy; Palladium; Prostate cancer; Sector analysis

Indexed keywords

PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN; PALLADIUM; RADIOISOTOPE;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; BRACHYTHERAPY IMPLANT; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; DOSIMETRY; EXPANDED POSTATE INDEX COMPOSITE QUESTIONNAIRE; GLEASON SCORE; HUMAN; MALE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE; PROSTATE BIOPSY; PROSTATE CANCER; QUALITY CONTROL; QUANTITATIVE ANALYSIS; QUESTIONNAIRE; RADIATION DOSE; RADIOTHERAPY PLANNING SYSTEM; SECTOR ANALYSIS; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT PLANNING; TREATMENT RESPONSE; CANCER STAGING; CLINICAL TRIAL; HEALTH CARE QUALITY; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; RADIATION RESPONSE; STANDARDS;

ADULT; AGED; BRACHYTHERAPY; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; PALLADIUM; PROSTATE; PROSTATIC NEOPLASMS; QUALITY ASSURANCE, HEALTH CARE; RADIOISOTOPES;

EID: 84892502379     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2013.04.001     Document Type: Article

References (20)

1. Hurwitz M.D., Halabi S., Ou S.S., et al. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: An initial report of CALGB 99809. Int J Radiat Oncol Biol Phys 2008, 72:814-819.
2. Koontz B.F., Chino J., Lee W.R., et al. Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer. Brachytherapy 2009, 8:191-196.
3. Khaksar S.J., Langley S.E., Lovell D., et al. Interstitial low dose rate brachytherapy for prostate cancer-A focus on intermediate- and high-risk disease. Clin Oncol (R Coll Radiol) 2006, 18:513-518.
4. Zelefsky M.J., Kuban D.A., Levy L.B., et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007, 67:327-333.
5. Frank S.J., Grimm P.D., Sylvester J.E., et al. Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: A survey of practice patterns in the United States. Brachytherapy 2007, 6:2-8.
6. Blasko J.C., Grimm P.D., Sylvester J.E., et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000, 46:839-850.
7. Merrick G.S., Wallner K.E., Butler W.M., et al. 20 Gy versus 44 Gy of supplemental external beam radiotherapy with palladium-103 for patients with greater risk disease: Results of a prospective randomized trial. Int J Radiat Oncol Biol Phys 2012, 82:e449-e455.
8. Stone N.N., Cesaretti J.A., Rosenstein B., et al. Do high radiation doses in locally advanced prostate cancer patients treated with 103Pd implant plus external beam irradiation cause increased urinary, rectal, and sexual morbidity?. Brachytherapy 2010, 9:114-118.
9. Frank S.J., Arterbery V.E., Hsu I.C.J., et al. American College of Radiology Appropriateness Criteria permanent source brachytherapy for prostate cancer. Brachytherapy 2011, 10:357-362.
10. Milosevic M., Voruganti S., Blend R., et al. Magnetic resonance imaging (MRI) for localization of the prostatic apex: Comparison to computed tomography (CT) and urethrography. Radiother Oncol 1998, 47:277-284.
11. Bice W.S., Prestidge B.R., Sarosdy M.F. Sector analysis of prostate implants. Med Phys 2001, 28:2561-2567.
12. Brown A.P., Pugh T.J., Swanson D.A., et al. Improving prostate brachytherapy quality assurance with MRI-based sector analysis in a phase II prospective trial. Brachytherapy 2013, 12:210-216.
13. Ciezki J.P., Reddy C.A., Garcia J., et al. PSA kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time. Int J Radiat Oncol Biol Phys 2006, 64:512-517.
14. Caloglu M., Ciezki J.P., Reddy C.A., et al. PSA bounce and biochemical failure after brachytherapy for prostate cancer: A study of 820 patients with a minimum of 3 years of follow-up. Int J Radiat Oncol Biol Phys 2011, 80:735-741.
15. Amdur R.J., Gladstone D., Leopold K.A., et al. Prostate seed implant quality assessment using MR and CT image fusion. Int J Radiat Oncol Biol Phys 1999, 43:67-72.
16. Chen L., Price R.A., Wang L., et al. MRI-based treatment planning for radiotherapy: Dosimetric verification for prostate IMRT. Int J Radiat Oncol Biol Phys 2004, 60:636-647.
17. Polo A., Cattani F., Vavassori A., et al. MR and CT image fusion for postimplant analysis in permanent prostate seed implants. Int J Radiat Oncol Biol Phys 2004, 60:1572-1579.
18. Samuelian J.M., Swanson D.A., Kudchadker R.J., et al. Long-term tumor control after brachytherapy for base-of-prostate cancer. J Contemp Brachytherapy 2011, 3:183-187.
19. Dattoli M., Wallner K., True L., et al. Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features. Cancer 2007, 110:551-555.
20. Da Pozzo L.F., Cozzarini C., Briganti A., et al. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: The positive impact of adjuvant radiotherapy. Eur Urol 2009, 55:1003-1011.